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Abstract
Background: Autoimmunity to neuronal proteins occurs in several neurological syndromes, where cellular and
humoral responses are directed to surface as well as intracellular antigens. Similar to myelin autoimmunity,
pathogenic immune response to neuroaxonal components such as neurofilaments may contribute to
neurodegeneration in multiple sclerosis.
Methods: We studied the immune response to the axonal protein neurofilament light (NF-L) in the experimental
autoimmune encephalomyelitis animal model of multiple sclerosis. To examine the association between T cells and
axonal damage, pathology studies were performed on NF-L immunized mice. The interaction of T cells and axons
was analyzed by confocal microscopy of central nervous system tissues and T-cell and antibody responses to
immunodominant epitopes identified in ABH (H2-Ag7) and SJL/J (H2-As) mice. These epitopes, algorithm-predicted
peptides and encephalitogenic motifs within NF-L were screened for encephalitogenicity.
Results: Confocal microscopy revealed both CD4+ and CD8+ T cells alongside damaged axons in the lesions of
NF-L immunized mice. CD4+ T cells dominated the areas of axonal injury in the dorsal column of spastic mice in
which the expression of granzyme B and perforin was detected. Identified NF-L epitopes induced mild
neurological signs similar to the observed with the NF-L protein, yet distinct from those characteristic of
neurological disease induced with myelin oligodendrocyte glycoprotein.
Conclusions: Our data suggest that CD4+ T cells are associated with spasticity, axonal damage and
neurodegeneration in NF-L immunized mice. In addition, defined T-cell epitopes in the NF-L protein might be
involved in the pathogenesis of the disease.
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Multiple sclerosis
Introduction
Multiple sclerosis (MS) is a chronic demyelinating and
neurodegenerative disease of the central nervous system
(CNS) widely considered due to aggressive, autoreactive
T cells and antibodies to myelin [1-3]. However, accumu-
lating evidence shows that immune responses to neuronal
and axonal proteins are also present in a wide range of neu-
rodegenerative disorders including MS [4-6]. That these
responses may contribute to axonal and neuronal damage,
pathological hallmarks of MS, is supported by observations
that immunization with neuronal antigens and transfer of
antibodies directed to neuronal and axonal proteins induce
neuronal damage in animals [7-10].
The lack of expression of molecules of the major histo-
compatibility complex (MHC) class II on neurons indicates
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that neurons cannot activate CD4+ cells in an antigen-
specific manner. However, neurons constitutively express
or readily upregulate expression of MHC class I during
inflammation, indicating that neurons may become
targets for CD8+ T cells [11]. Conceptually, both CD4+
and CD8+ T cells could mediate attack on axons and
neurons, either by direct contact via antigen-independent
interactions or as a result of collateral damage [12].
Activated T cells in the CNS are reported to produce
cytotoxic molecules as well as glutamate, nitric oxide
and reactive oxygen species that could contribute to
the damage and progressive neurodegeneration observed
in MS and other neurodegenerative diseases in which
inflammation has been described [13-15]. In addition,
activation of B cells might lead to the production of
specific antibodies to neuronal antigens that could also
contribute to the damage and progressive neurode-
generation [16].
To examine the mechanisms of autoimmunity to neu-
rons we have developed a model of autoimmune induced
axonal and neuronal damage following immunization of
mice with the neuronal cytoskeletal protein neurofilament
light (NF-L) [7]. Whether T-cell responses to neuroaxonal
components are pathogenic in MS is as yet unknown;
although we have recently shown that NF-L is phagocy-
tosed by MHC class II+ microglia/macrophages in MS
brain lesions [17], indicating a potential source by which
autoreactive T cells could become reactivated in MS. In
mice, we have shown that autoimmunity to NF-L causes
spasticity and neurodegeneration and that axonal damage
is a direct consequence of such responses [7,8]. Infiltration
of CD3+ T cells and B220+ cells mainly localized in the
dorsal column of the spinal cord of NF-L immunized
mice was also observed [8]. Likewise, immunoglobulin
deposits were observed into the axons in mice immu-
nized with NF-L protein [7].
In the present study, we characterized the T-cell infil-
trates in the CNS of spastic mice. Both CD4+ and CD8+
T cells were found in close association to axons, although
CD4+ T cells dominated the infiltrates in lesions. In
addition, increased perforin expression and cells posi-
tive for granzyme B could be observed in the spinal cord
of mice immunized with NF-L. Furthermore, NF-L pep-
tides were screened for T-cell and B-cell responses in
ABH (H2-Ag7) and SJL/J (H2-As) mice, and the patho-
genic potential of these peptides and predicted binding
motifs to H2-Ag7 present in the NF-L sequence were
investigated.
In summary, our study reveals that T cells associated
with the expression of cytotoxic molecules are present
in lesions in the dorsal columns of spastic mice immu-
nized with NF-L and we show, for the first time, that ac-
tive immunization with defined NF-L peptides induced
neurological disease in ABH mice.
Materials and methods
Mice
Male and female 10-week-old Biozzi ABH (H-2dq1) and
SJL/J (H-2s) mice were obtained from Harlan (Bicester,
UK) and Charles River laboratories (Kent, UK) or were bred
at QMUL (London, UK). All procedures were performed in
accordance with the UK Animals (Scientific Procedures)
Act (1986) and approved by the local ethics committee.
All procedures were performed following Institutional
ethical review in accordance to the United Kingdom
Animals (Scientific Procedures) Act (1986) and European
Union Directive 2010/63/EU. Animals were housed and
monitored consistent with the principles of the ARRIVE
guidelines as described previously [18].
Antigens
Spinal cord homogenate (SCH) prepared from 60 ABH mice
was lyophilized and reconstituted in PBS as described previ-
ously [18]. rmNF-L was prepared as described previously
[17]. Overlapping 16-amino-acid peptides (Table 1) based on
the mouse protein sequence (NCBI protein ID: NP035040)
and myelin oligodendrocyte glycoprotein (MOG35–55) pep-
tide (MEVGWYRSPFSRVVHLYRNGK) were synthesized
as peptide amides (CONH2) (Cambridge Research Bio-
chemicals Ltd, Billingham, UK).
Induction of experimental autoimmune encephalomyelitis
Mice were injected subcutaneously with 1 mg SCH,
200 μg rmNF-L, 200 μg MOG35–55 or rmNF-L and
MOG35–55 (1:1), or pools of 30 μg each peptide emulsified
with incomplete Freund’s adjuvant (Difco Laboratories,
Detroit, Michigan, USA) supplemented with 48 μg Myco-
bacterium tuberculosis and 6 μg Mycobacterium
butyricum (Difco Laboratories) on day 0 and day 7 as
described previously [19]. Control mice were immu-
nized with complete Freund’s adjuvant (CFA) only. All
mice were injected with 200 ng Bordetella pertussis toxin
(Sigma, St. Louis, Missouri, USA) intraperitoneally, imme-
diately after immunization and 24 hours later.
To identify encephalitogenic epitopes, four to six mice
were immunized with rmNF-L, individual or pooled
peptides. To optimize identification, sequences containing
motifs that bind to or interact with H2-Ag7 were selected
as described previously [19]. The Rankpep server was
additionally used to predict binding to H2-Ag7 [20].
Mice were monitored daily and scored according to a
neurological scale: 0, normal; 0.5, partial loss of tail tone;
1, paralysis or spasticity of the tail; 2, impaired righting
reflex; 3, paralysis or spastic paresis of one limb; 4, par-
alysis or spastic paresis of two limbs; and 5, moribund
[7,18]. Mice were sacrificed by carbon dioxide inhalation
and brains and spinal cords snap-frozen in liquid nitro-
gen or processed for pathology [7].
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Immunohistochemistry
Sections (3 μm) from snap-frozen spinal cord tissues
were fixed with acetone and incubated overnight at 4°C
with mAb directed to CD4 (YTS 191.1.2), CD8 (YTS
169AG; ImmunoTools, Friesoythe, Germany), MHC-I
antigens (HM1091; Hycult Biotech, Plymouth Meeting,
PA, USA) or biotinylated MHC-II (OX 6, a kind gift of
Jack van Horssen, VU University Medical Center) diluted in
antibody diluent (Immunologic; Duiven, The Netherlands).
After washing, endogenous peroxidase was blocked with
0.3% H2O2 in PBS. Sections stained for CD4, CD8 and
MHC-I were incubated with biotinylated rabbit anti-
rat Ig (Dako, Glostrup, Denmark) for 1 hour, followed
by peroxidase-coupled avidin–biotin complex (ABC kit;
Vector Laboratories, Burlingame, CA, USA). Sections
stained with biotinylated MHC-II were incubated with
streptavidin–horseradish peroxidase complex (Dako) for
1 hour. All secondary antibodies were visualized with
3,3′-diaminobenzidine. Antibodies were prescreened on
brain, liver, lung, spleen and tonsil tissues and isotype
control mAb served as negative control. The percentage
of CD4+ and CD8+ T cells were counted at 25× objective
at three levels of the spinal cord.
For immunofluorescence, sections were incubated
with blocking solution (CleanVision IHC/ICC; Immuno-
logic) containing 10% normal goat serum for 2 hours,
washed in PBS and incubated with mAb to NF-L (10H9),
SMI-32 (Covance, Princeton, NJ, USA) or NeuN (Merck
Millipore; Darmstadt, Germany) and CD3 (CD3-12; Serotec,
Oxford, UK), CD4 (YTS 191.1.2) or CD8 (YTS 169AG;
ImmunoTools) overnight at 4°C. After washing in PBS,
sections were incubated with goat anti-mouse IgG1
Alexa 594 or goat anti-rat IgG Alexa 488 (Invitrogen;
Paisley, UK) for 60 minutes at room temperature.
Sections were viewed using confocal laser scanning mi-
croscopy (Leica DMI6000; Rijswijk, The Netherlands).
Image processing was performed using NIH Image J soft-
ware [21].
Granzyme B staining was performed on paraffin-
embedded sections (4 μm). In brief, sections were
deparaffinized and rinsed in H2O. Subsequently, endogen-
ous peroxidase was blocked as described above. After
rinsing in PBS, antigen retrieval in Tris–ethylenediamine
tetraacetic acid buffer (pH 9.0) was performed in a micro-
wave followed by incubation with 10% normal goat serum.
Sections were incubated overnight at 4°C with polyclonal
rabbit anti-granzyme B (ab4059; Abcam; Cambridge, UK)
in 1% BSA. Subsequently, sections were washed in PBS
and incubated with secondary antibody Envision anti
Rabbit labeled with horseradish peroxidase (K4002; Dako)
for 30 minutes and visualized with 3,3′-diaminobenzidine.
Reverse transcriptase polymerase chain reaction
Spinal cords from control and NF-L immunized ABH
mice were dissolved in lysis buffer (NucleoSpin RNA/
Protein kit; Machery-Nagel GmbH, Düren, Germany) and
homogenized with 1.4 mm ceramic beads (Precellys 24;
Peqlab Biotechnologie GmbH, Erlangen, Germany) at
5000 rpm for 15 seconds. Subsequently, RNA was iso-
lated using NuceloSpin (Macherey-Nagel) according to
the manufacturer’s recommendations. Purity was con-
firmed using 260:280 OD ratios (Nano-Drop 1000; Peqlab
Biotechnologie GmbH). RT reactions were performed
with the MMLV RT-kit and random hexanucleotide
Table 1 Sequences of mouse neurofilament-light peptidesa
Sequence Amino acid Sequence Amino acid
1 to 16 SSFGYDPYFSTSYKRR 273 to 288 MQNAEEWFKSRFTVLT
9 to 24 FSTSYKRRYVETPRVH 281 to 296 KSRFTVLTESAAKNTD
17 to 32 YVETPRVHISSVRSGY 289 to 304 ESAAKNTDAVRAAKDE
25 to 40 ISSVRSGYSTARSAYS 297 to 312 AVRAAKDEVSESRRLL
33 to 48 STARSAYSSYSAPVSS 305 to 320 VSESRRLLKAKTLEIE
41 to 56 SYSAPVSSSLSVRRSY 313 to 328 KAKTLEIEACRGMNEA
49 to 64 SLSVRRSYSSSSGSLM 321 to 336 ACRGMNEALEKQLQEL
57 to 72 SSSSGSLMPSLENLDL 329 to 344 LEKQLQELEDKQNADI
65 to 80 PSLENLDLSQVAAISN 337 to 352 EDKQNADISAMQDTIN
73 to 88 SQVAAISNDLKSIRTQ 345 to 360 SAMQDTINKLENELRS
81 to 96 DLKSIRTQEKAQLQDL 353 to 368 KLENELRSTKSEMARY
89 to 104 EKAQLQDLNDRFASFI 361 to 376 TKSEMARYLKEYQDLL
97 to 112 NDRFASFIERVHELEQ 369 to 384 LKEYQDLLNVKMALDI
105 to 120 ERVHELEQQNKVLEAE 377 to 392 NVKMALDIEIAAYRKL
113 to 128 QNKVLEAELLVLRQKH 385 to 400 EIAAYRKLLEGEETRL
121 to 136 LLVLRQKHSEPSRFRA 393 to 408 LEGEETRLSFTSVGSI
129 to 144 SEPSRFRALYEQEIRD 401 to 416 SFTSVGSITSGYSQSS
137 to 152 LYEQEIRDLRLAAEDA 409 to 424 TSGYSQSSQVFGRSAY
145 to 160 LRLAAEDATNEKQALQ 417 to 432 QVFGRSAYSGLQSSSY
153 to 168 TNEKQALQGEREGLEE 425 to 440 SGLQSSSYLMSARSFP
161 to 176 GEREGLEETLRNLQAR 433 to 448 LMSARSFPAYYTSHVQ
169 to 184 TLRNLQARYEEEVLSR 441 to 456 AYYTSHVQEEQTEVEE
177 to 192 YEEEVLSREDAEGRLM 449 to 464 EEQTEVEETIEATKAE
185 to 200 EDAEGRLMEARKGADE 457 to 472 TIEATKAEEAKDEPPS
193 to 208 EARKGADEAALARAEL 465 to 480 EAKDEPPSEGEAEEEE
201 to 216 AALARAELEKRIDSLM 473 to 488 EGEAEEEEKEKEEGEE
209 to 224 EKRIDSLMDEIAFLKK 481 to 496 KEKEEGEEEEGAEEEE
217 to 232 DEIAFLKKVHEEEIAE 489 to 504 EEGAEEEEAKDESEDT
225 to 240 VHEEEIAELQAQIQYA 497 to 512 AKDESEDTKEEEEGGE
233 to 248 LQAQIQYAQISVEMDV 505 to 520 KEEEEGGEGEEEDTKE
241 to 256 QISVEMDVSSKPDLSA 513 to 528 GEEEDTKESEEEEKKE
249 to 264 SSKPDLSAALKDIRAQ 521 to 536 SEEEEKKEESAGEEQV
257 to 272 ALKDIRAQYEKLAAKN 529 to 544 ESAGEEQVAKKKD
265 to 280 YEKLAAKNMQNAEEWF
aMouse neurofilament-light sequence (NCBI reference sequence: NP035040).
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primers (Invitrogen) and gene expression was mea-
sured using Taq-Polymerase (Biomol GmbH, Hamburg,
Germany).
Primers for perforin amplification (sense, 5′-CTGCCA
CTCGGTCAGAATG-3′; antisense, 5′-CGGAGGGTAG
TCACATCCAT-3′) were used at annealing temperature
of 59°C, amplifying an 88-base-pair fragment. Expres-
sion levels of the reference gene hypoxanthine guanine
phosphoribosyl transferase were used as control. Primers
for hypoxanthine guanine phosphoribosyl transferase
amplification (sense, 5′-GCTGGTGAAAAGGACCTCT-3′;
antisense: 5′-CACAGGACTAGAACACCTGC-3′) were
used at an annealing temperature of 60°C, amplifying a
248-base-pair fragment, and primers for 18sRNA ampli-
fication (sense, 5′-CGGCTACCACATCCAAGGAA-3′;
antisense, 5′-GCTGGAATTACCGCGGCT-3′) were used
at an annealing temperature of 60°C, amplifying a 187-
base-pair fragment. Gene expression was performed using
RT-PCR technology (Bio-Rad; Munich, Germany) with
SYBR green (SensiMix™; Bioline; Luckenwalde, Germany),
as published previously [22].
T-cell proliferation assays
ABH and SJL/J mice were immunized with rmNF-L in
CFA or CFA only (n = 4 per group). Spleen cells were col-
lected 10 days after priming and single-cell suspensions
(3 × 105/ml) cultured in RPMI medium (Gibco, Invitrogen;
Paisley, UK) with 5% FCS (Gibco, Invitrogen), 2 mM
L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin,
5 mM Hepes, and 5 × 10–5 M 2-mercaptoethanol (Gibco,
Invitrogen). Cells were incubated with NF-L peptides or
rmNF-L for 72 hours. Proliferation was determined by
incorporation of [3H]-thymidine (GE Healthcare, Uppsala,
Sweden). Stimulation indices (SIs) were calculated as
the proliferative response in the presence of antigen
divided by the response in the absence of antigen. SI in
the CFA control group ranged from 0.6 to 1.1. Positive
stimulation was defined as SI >1.5.
Enzyme-linked immunosorbent assay
To identify B-cell epitopes in NF-L, Biozzi ABH and
SJL/J mice (n = 4 per group) were immunized with
rmNF-L protein in complete adjuvant and serum was
collected on day 15 post immunization. The mouse
immune sera were tested for their reactivity to NF-L
overlapping peptides. Nunclon plates (Nunc, Roskilde,
Denmark) were coated overnight at 4°C with 10 μg/ml
mouse NF-L peptides or rmNF-L protein, in carbonate
buffer. Plates were washed twice in PBS and blocked for
1 hour at 37°C with 2% BSA/PBS. After blocking, ABH or
SJL/J immune sera, diluted 1:100 in 1% (BSA/PBS), were
added and incubated for 1 hour at room temperature.
After washing in PBS–Tween 0.1%, the plates were incu-
bated for 1 hour at room temperature with horseradish
peroxidase-conjugated rabbit anti-mouse Ig (Dako). The
reaction product was developed with TMB substrate
(Thermo Fisher Scientific; Loughborough, UK) and stopped
by the addition of 2 M hydrochloric acid. The absorbance
was measured at 450 nm, using a Synergy HT microplate
reader (Bio-Tek instruments; Winooski, Vermont, USA).
Background values were obtained by the reactivity of im-
mune serum on peptide uncoated wells. An absorbance
above the mean plus three standard deviations of the back-
ground reactivity was taken as positive.
Statistical analysis
For comparison of clinical experimental autoimmune
encephalomyelitis (EAE) scores, significance between the
groups was determined by nonparametric Mann–Whitney
rank-sum test (SigmaStat; Systat Software Inc., San Jose,
CA, USA). Data represent the mean ± standard error of
the mean (**P <0.01, *P <0.05).
Results
CD4+ and CD8+ T cells are associated with neuronal/axonal
damage in spastic mice
To examine the presence of T cells in the CNS during
disease, CD4+ or CD8+ T cells within the lesions of NF-L
immunized mice at the peak of disease were examined.
Using immunohistochemistry, the ratio of CD4+ and CD8+
T cells in the lesions was determined (Figure 1A, B, respect-
ively). We observed that significantly more CD4+ T cells
were present within the lesions in a ratio of 9:1 CD4+:CD8+
T cells (data not shown). To support a role for CD8+ T cells
we examined the expression of MHC class I in the spinal
cord of diseased mice. In contrast to expression of MHC
class I antigens on inflammatory cells in the lesion as well
as perivascular cells (Figure 1C) and microglia in normal-
appearing white matter (Figure 1D), there was no evidence
of MHC-class I antigen expression on neurons or axons
in the lesions (Figure 1E, F) or in normal-appearing tissues
(data not shown). Likewise, while MHC class II was
expressed on inflammatory cells in the blood vessels
and in the parenchyma, being present on ramified cells
resembling microglia (Figure 1G), no expression on neurons
and axons was observed (Figure 1H, I), as has been shown
before in normal or pathological tissues during EAE [23].
To examine the interaction of T cells and axons we
used confocal microscopy of CNS tissues from spastic
mice. We observed a close association of CD3+ T cells
aligning with possible damaged axons as indicated by
SMI-32 staining (Figure 2A), in which there was close
association between the T cell and the axon (Figure 2A,
insert). In cross-sections of the lesion, CD4+ T cells were
observed within areas of axonal damage (Figure 2B) and
frequently observed between axons with increased im-
munoreactivity for SMI-32 and neurofilament, indicating
axonal damage (Figure 2C, D). While CD8+ T cells were
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also observed between thickened axons in the lateral
funiculus and adjacent to Neu-N+ neurons in the spinal
cord (Figure 2E, F), these were rare as compared with
CD4+ T cells.
Cytotoxic molecules are present in the spinal cord of NF-L
immunized mice
To examine the potential mechanisms of T-cell-mediated
axonal damage, the expression of the cytotoxic molecules
granzyme B and perforin was examined in the spinal cord
of spastic mice. Immunostaining revealed the expression
of granzyme B in spinal cord lesions of mice immunized
with NF-L (Figure 3A). Immunodetection of perforin in
mouse CNS was not possible due to lack of specific mAbs.
Instead, RT-PCR on spinal cord tissues was performed
and showed that perforin mRNA levels were increased
in rmNF-L immunized mice compared with controls
(Figure 3B). In addition, granzyme B and perforin were
expressed by peripheral CD4+ T cells from NF-L immunized
mice compared with CD8+ T cells (data not shown).
Figure 1 T cells in lesions of spastic mice. Immunohistochemistry showing (A) CD8+ and (B) CD4+ T cells in the dorsal column of a spastic mouse.
(C) to (F) Major histocompatibility complex (MHC) class I antigen staining expressed on (C) endothelial cells, and (D) microglia (E, F), but not on
neurons. (G) to (I) MHC class II staining on ramified cells resembling microglia but not neurons (H, I). A to E, G to H, bar = 10 μm; F and I, bar = 5 μm.
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Autoimmunity to NF-L exacerbates MOG35–55 experimental
autoimmune encephalomyelitis in ABH mice
To increase the likelihood of exposing NF-L protein in the
CNS, ABH mice were co-immunized with MOG35–55 to
induce myelin damage (Figure 4). While SCH induced
classical EAE about 11 days after immunization, co-
immunization of rmNF-L with MOG35–55 induced sig-
nificantly augmented disease in which spasticity was
observed on days 16 and 17 (P = 0.005), indicating that
myelin damage may first be necessary to expose neur-
onal antigens. Within this timeframe, mice immunized
with rmNF-L only did not develop clinical disease as
we have reported previously [7]. However, by day 21,
NF-L immunized mice did develop neurological signs
of disease with a mean day of onset 19.8 ± 1.6, EAE score
1.5 ± 1.0, group score 0.5 ± 0.4 and an EAE incidence
of 50%.
Immunodominant B-cell and T-cell epitopes of neurofilament
light in mice
To determine immunodominant epitopes in the NF-L
protein, antibody and T-cell responses to synthetic 16-mer
overlapping peptides spanning the mouse NF-L sequence
(Table 1) were screened in ABH and SJL/J mice immu-
nized with rmNF-L in CFA [19]. Since we have seen before
that immunization with NF-L in Biozzi mice can result
in antibody production and binding to axons, it was
of interest to screen the antibody responses to the
overlapping peptides [7]. Antibody reactivity to NF-L
peptides in both strains of mice revealed an immuno-
dominant region that corresponds to the overlapping
region (NF-L amino acids 169 to 208) and the single
region (amino acids 169 to 184) in ABH and SJL/J mice
respectively (Figure 5A, B). This region is located in the
coil 1b domain of NF-L. In line with our observations,
these motifs (amino acids 154 to 195) are likely to be
linear B-cell epitopes according to the BCPred predic-
tion algorithm [24]. In SJL/J mice, NF-L specific anti-
bodies also reacted to the single peptides amino acids
41 to 56 and amino acids 345 to 360 (Figure 5B). In both
strains, the mean absorbance values for antibody re-
sponse to rmNF-L protein were within the optical dens-
ity range of 1.21 to 1.34.
Immunodominant T-cell responses to two dominant
regions, amino acids 241 to 288 and 345 to 368, were
observed in ABH mice (Figure 6A). In comparison, T-cell
responses in SJL/J mice were observed to amino acids 241
to 288 (Figure 6B). In both strains, the SIs were lower than
responses to rmNF-L alone (SI = 5 to 10). These results
are in line with data using overlapping 15-mer peptides
of NF-L in ABH mice (data not shown), indicating that
immunodominant epitopes reside within the rod domain
(linker 2 and coil 2B) of NF-L. No overlapping peptide
induced significant proliferation in cells from CFA im-
munized mice.
Pathogenicity of immunodominant epitopes
To determine the pathogenicity of immunodominant
epitopes, ABH mice were immunized with individual NF-L
peptides spanning the T-cell immunodominant region
(amino acids 241 to 272) or with a pool of immuno-
dominant B-cell epitopes. In contrast to SCH-induced
Figure 2 T cells associated with axonal damage in spastic mice. Confocal images of (A) CD3+ T cell (green) in contact with SMI32+ axon
(red). (B, C) CD4+ T cells in area of axonal damage and (D) next to swollen NF-L+ axons. (E) CD8+ T cells between NF-L+ axons and (F) Neu-N+
neurons in the spinal cord. A, E, F, bar = 5 μm; B, C, D, bar = 25 μm.
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EAE, immunization of ABH mice with amino acids 241
to 256, 249 to 264, 257 to 272, 345 to 360 and 353 to
368 induced spasticity of the tail and hind limbs in line
with studies using rmNF-L (Table 2, panel A) [7].
Immunization with NF-L peptides also induced a de-
layed onset of clinical signs occurring 10 days later than
SCH-induced EAE (Table 2, panel A). Rota-rod studies
did not reveal additional signs of neurological disease
(data not shown). SJL/J mice immunized with rmNF-L
also developed very mild clinical disease of spasticity
(data not shown). The pathogenic potential of NF-L
peptides was also observed with some, but not all, pep-
tides predicted to bind with H2-Ag7 (Table 2, panel B).
No significant effect was observed after immunization
with the immunodominant B-cell epitopes (amino acids
169 to 208) (Additional file 1).
Additionally, the capacity of NF-L-specific T cells to
transfer spasticity was tested in ABH mice. Lymph node
and spleen cells from rmNF-L-immunized ABH mice were
Figure 3 Production of cytotoxic molecules in spastic mice. (A) Granzyme B-positive staining (indicated by arrows) was performed on
paraffin-embedded spinal cord sections: bar = 10 μm. (B) Gel electrophoresis of PCR products show perforin expression is increased in spastic
mice (hypoxanthine guanine phosphoribosyl transferase (HPRT) = internal control). NF-L, neurofilament light.
Figure 4 Augmentation of MOG35–55-induced experimental
autoimmune encephalomyelitis by neurofilament light. ABH
mice were immunized with spinal cord homogenate, MOG35–55,
rmNF-L or rmNF-L and MOG35–55. **P <0.005; Mann–Whitney U test.
NF-L, neurofilament light.
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collected 12 days after immunization and stimulated for
10 days in vitro with rmNF-L. Activated cells were
adoptively transferred into irradiated naïve recipients
and followed until day 25. Mild signs of disease (score 0.5)
were observed in two of seven mice revealing the patho-
genic potential of T cells to NF-L (data not shown).
Figure 5 B-cell responses to neurofilament light peptides in ABH and SJL/J mice. (A) ABH mice and (B) SJL/J mice were immunized with rmNF-L
and serum antibody reactivity to NF-L peptides was measured on day 10. Mean absorbance (optical density (OD) >0.25) was considered positive.
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Discussion
Accumulating evidence indicates that as well as myelin-
specific T cells, neuronal-specific T cells may gain access
to the CNS and contribute to neurodegeneration. Immune
responses to neurons are reported in Rasmussen’s enceph-
alitis [25], Alzheimer’s disease [26], Parkinson’s disease
[27] and paraneoplastic disorders [5], underscoring the
potential role of pathogenic neuronal-reactive T cells in
Figure 6 T-cell responses to NF-L peptides in ABH and SJL/J mice. (A) ABH mice and (B) SJL/J mice were immunized with rmNF-L and T-cell
proliferation to NF-L peptides was measured on day 10. Stimulation index >1.5 was considered positive.
Puentes et al. Journal of Neuroinflammation 2013, 10:118 Page 9 of 13
http://www.jneuroinflammation.com/content/10/1/118
MS in which axonal damage correlates with disability. To
examine the role of T cells in neurodegeneration, we have
studied autoimmune-meditated neurodegeneration in mice
immunized with NF-L in which spasticity and paralysis,
clinical features characteristic of MS, are observed [7,8]. In
previous studies, infiltration of CD3+ and B220+ cells and
immunoglobulin deposits were observed in spinal cord le-
sions of NF-L immunized mice [7].
In this study, we aimed to further investigate the cellular
and humoral immune response in the mouse model of
NF-L-induced neurodegeneration. Immunohistochemistry
revealed the association of both CD4+ and CD8+ T cells
with neuronal damage and the expression of cytotoxic
molecules in the CNS. We also identify immunodominant
regions and encephalitogenic epitopes on the NF-L pro-
tein. Together, our data support the accumulating evi-
dence that T cells play a role in neuronal and axonal
damage in neurodegenerative disorders. Adoptive trans-
fer experiments to test the ability of NF-L peptide-
specific T cells to induce disease would be of interest in
future studies.
A pre-requisite for antigen-specific CD8+ cytotoxic
damage of neurons is the expression of MHC class I mole-
cules. Strong evidence exists of MHC class I on neurons,
neurites and axons, revealing differential expression de-
pending on neuronal subtype, development stage and the
inflammatory stimulus. MHC class I expression is highly
upregulated on neurons following IFNγ treatment but not
TNFα [28]. Intriguingly, CD8+ T cells directed to NF-L
generated from spastic mice produce high levels of IFNγ
[4], indicating that T cells to NF-L could trigger pro-
gressive neurodegeneration. Further support for T-cell-
mediated neuronal damage comes from the finding that,
in EAE, myelin-reactive T cells are activated by neuro-
filament peptides [29]. Such interaction between T cells and
neurons may induce antigen-specific lysis of neurons [30]
or dysfunction by impairing electrical signaling [31] and
induction of rapid microtubule axonal destabilization
[32]. In the spastic model it is unlikely that antigen-
specific CD8+ T-cell activation leads to neuronal damage
since MHC class I was not present on neurons, either in
the lesions or in normal appearing tissue. While it is
unlikely that CD4+ T cells induce neuronal death in an
antigen-specific fashion, as neurons do not express MHC
class II, pathogenic CD4+ T cells expressing NKG2C could
injury neurons and axons expressing HLA-E, as reported
for oligodendrocytes in MS [33].
T-cell-mediated neuronal damage may alternatively occur
via antigen-independent interactions involving Fas–FasL,
TRAIL, CD11a and CD40. In culture, polyclonally activated
CD4+ and CD8+ T cells are cytotoxic to human neurons
[30,32], underscoring the potential pathogenic role of both
Table 2 Pathogenic neurofilament-light peptides in ABH micea
Antigen/peptides Number with EAE Mean group scoreb Mean EAE scorec Mean day of onset
Panel A
SCH 4/4 4.0 ± 0.0* 4.0 ± 0.0 15.3 ± 0.3
rmNF-L 4/5 0.7 ± 0.3* 0.9 ± 0.2 31.0 ± 1.4
241 to 256 1/5 0.1 ± 0.1 0.5 ± N/A 21.0 ± N/A
249 to 264 5/5 0.9 ± 0.3* 0.9 ± 0.3 25.6 ± 6.4
257 to 272 3/5 0.4 ± 0.2 0.7 ± 0.2 29.3 ± 0.6
265 to 280 0/5 N/A N/A N/A
273 to 288 0/5 N/A N/A N/A
345 to 360 3/5 0.7 ± 0.3 1.2 ± 0.3 29.3 ± 0.3
353 to 368 3/5 0.5 ± 0.2 0.8 ± 0.2 25.7 ± 4.4
Panel B
129 to 144 2/5 0.2 ± 0.1 0.5 ± 0.0 18.5 ± 6.5
297 to 312 2/5 0.2 ± 0.1 0.5 ± 0.0 30.5 ± 0.5
313 to 328 0/5 N/A N/A N/A
113 to 128, 281 to 296, 289 to 304, 321 to 336 (4) 3/4 0.9 ± 0.4 1.2 ± 0.3 28.7 ± 0.7
201 to 216, 377 to 392, 457 to 472 (3) 0/5 N/A N/A N/A
Panel C
CFA 0/5 N/A N/A N/A
aAnimals were injected with (panel A) 200 μg spinal cord homogenate (SCH), rmNF-L or single immunodominant NF-L peptides in CFA or with (panel B) peptides
in Complete Freund’s adjuvant (CFA) predicted to bind H2-Ag7 or with (panel C) CFA alone.
bMean ± standard error of the mean (SEM) of the maximum experimental autoimmune encephalomyelitis (EAE) score of animals in the group.
cMean ± SEM of the maximum EAE score of affected animals.
N/A, not applicable. *P <0.05, compared with CFA immunized mice.
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CD4+ and CD8+ T cells. In line with these studies, our
results show that granzyme B and perforin are present
in the lesions of spastic mice, indicating that neuronal
damage is more likely due to antigen-independent mecha-
nisms. The predominance of CD4+ T cells in the lesions
of NF-L immunized mice may be due to selective re-
cruitment or selective depletion of CD8+ T cells [34].
Moreover, the ratio between the T-cell subsets in the
lesions in our model is similar to myelin-induced EAE
[35]. Further studies on the expression of cytotoxic
molecules in T-cell subpopulations in the CNS of NF-L
immunized mice will be necessary.
Our observations that co-immunization with MOG and
NF-L leads to exacerbated disease is pertinent to what
might occur in MS during myelin damage, in which neu-
rons may be more vulnerable to immune responses to
neuronal antigens. In this way, the course of neuronal
degeneration might be accelerated in the presence of
NF-L reactive T cells [4] and antibodies to NF in MS [36].
EAE studies have been instrumental in identifying
the role of T cells and antibodies to myelin in disease.
These have revealed important information about pep-
tide:MHC:T-cell receptor interactions crucial for devel-
opment of tolerance regimes using altered peptide ligands
or tolerogenic routes for delivery of pathogenic peptides
to modulate myelin-specific T cells [37,38]. These ap-
proaches have proved effective in chronic EAE models,
preventing the clinical relapses, but do not control pro-
gressive disease [37], indicating that mechanisms other
than myelin autoimmunity, such as autoimmunity to neur-
onal proteins, are involved in neurodegeneration in MS.
In ABH mice, immunization with MOG and proteolipid
protein readily induces neurological disease in which flac-
cid paralysis and preferential myelin loss is observed. In
contrast, immunization with NF-L protein induces a
predominantly spastic disease in which neuronal dam-
age is the primary pathological feature. To determine the
pathogenic potential of NF-L peptide, we used a peptide
mapping approach and identified a peptide core within
the NF-L protein that contains similar elements to previ-
ously defined H2-Ag7 motifs within myelin basic protein,
MOG and proteolipid protein (Table 3) [19]. This sup-
ports many of the predictions made by computer mod-
eling of peptide H2–Ag7 interactions [39]. Similar to the
finding following immunization with myelin antigens
[19], several encephalitogenic epitopes were identified
in NF-L immunized ABH mice. One should note that
when using overlapping peptides, inappropriate sequence
alignment could mask encephalitogenic epitopes or in-
duce peptide epitopes to become tolerogenic [40]. In
addition, neurofilament modulates oligodendrocyte pro-
liferation and differentiation [41], thereby masking the
possible pathogenic impact of these proteins. Peptide
mapping approaches have identified immunodominant
epitopes of myelin basic protein in mice and humans
and prompted tolerance strategies to myelin basic protein-
specific T cells in MS. Current studies are underway to
identify T-cell responses to NF-L epitopes in MS patients
who respond to the NF-L protein [4]. These studies may
reveal whether such responses are present in subtypes
of MS or correlate with extent of cognitive changes or
progressive disease. Such findings may be key to the
development of personal therapeutic approaches using
tolerance regimens.
In conclusion, we show that peptide epitopes of NF-L in-
duce neurological disease and that potentially pathogenic
CD4+ T cells dominate the lesions of NF-L immunized
mice, a model for immune-mediated neurodegeneration.
Our data suggest that, similar to peptide therapies
targeting myelin responses [43], immune therapies targeting
neuronal-specific T cells could thus be beneficial in reducing
neurodegeneration in inflammatory disorders such as MS.
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